Treosulfan with fludarabine recommended for malignant disease before allogeneic stem cell transplant
NICE Technology appraisal guidance [TA640] shows some groups are less likely to die from the transplant or associated complications if they have treosulfan and fludarabine instead of busulfan and fludarabine.
Published
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date
